JP Morgan Chase’s DexCom DXCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$233M Sell
3,325,095
-2,674,375
-45% -$178M 0.01% 696
2026
Q1
$371M Sell
5,999,470
-216,931
-3% -$15.1M 0.02% 491
2025
Q4
$413M Buy
6,216,401
+2,644
+0% +$171K 0.03% 450
2025
Q3
$418M Buy
6,213,757
+59,165
+1% +$4.68M 0.03% 463
2025
Q2
$537M Buy
6,154,592
+2,013,099
+49% +$158M 0.04% 405
2025
Q1
$283M Sell
4,141,493
-199,886
-5% -$16.3M 0.02% 562
2024
Q4
$338M Sell
4,341,379
-1,208,929
-22% -$89.5M 0.03% 493
2024
Q3
$372M Sell
5,550,308
-1,160,675
-17% -$95.3M 0.03% 475
2024
Q2
$761M Buy
6,710,983
+1,014,387
+18% +$128M 0.06% 275
2024
Q1
$790M Buy
5,696,596
+43,977
+0.8% +$5.53M 0.07% 272
2023
Q4
$701M Buy
5,652,619
+242,352
+4% +$24.8M 0.07% 279
2023
Q3
$505M Sell
5,410,267
-7,262,910
-57% -$819M 0.06% 312
2023
Q2
$1.63B Buy
12,673,177
+1,908,349
+18% +$231M 0.18% 126
2023
Q1
$1.25B Buy
10,764,828
+117,732
+1% +$13.2M 0.15% 147
2022
Q4
$1.21B Buy
10,647,096
+399,056
+4% +$43.8M 0.16% 142
2022
Q3
$825M Sell
10,248,040
-135,409
-1% -$11.5M 0.12% 181
2022
Q2
$774M Sell
10,383,449
-978,243
-9% -$89.3M 0.11% 200
2022
Q1
$1.45B Sell
11,361,692
-370,428
-3% -$40.5M 0.18% 132
2021
Q4
$1.57B Sell
11,732,120
-241,020
-2% -$34.6M 0.18% 128
2021
Q3
$1.64B Sell
11,973,140
-3,020,880
-20% -$381M 0.2% 114
2021
Q2
$1.6B Buy
14,994,020
+3,521,436
+31% +$338M 0.19% 126
2021
Q1
$1.03B Sell
11,472,584
-762,900
-6% -$71.6M 0.14% 169
2020
Q4
$1.13B Sell
12,235,484
-55,952
-0.5% -$5M 0.17% 141
2020
Q3
$1.24B Buy
12,291,436
+153,276
+1% +$16M 0.21% 107
2020
Q2
$1.23B Sell
12,138,160
-1,748,352
-13% -$156M 0.24% 96
2020
Q1
$935M Sell
13,886,512
-535,464
-4% -$33.3M 0.22% 97
2019
Q4
$789M Sell
14,421,976
-3,532
-0% -$168K 0.15% 149
2019
Q3
$538M Sell
14,425,508
-2,773,704
-16% -$108M 0.11% 206
2019
Q2
$627M Sell
17,199,212
-1,046,860
-6% -$32.9M 0.12% 174
2019
Q1
$543M Sell
18,246,072
-2,653,928
-13% -$93.3M 0.11% 200
2018
Q4
$626M Buy
20,900,000
+7,276,568
+53% +$231M 0.14% 152
2018
Q3
$487M Buy
13,623,432
+2,079,004
+18% +$64.5M 0.09% 231
2018
Q2
$274M Buy
11,544,428
+1,191,500
+12% +$25.3M 0.06% 349
2018
Q1
$192M Buy
10,352,928
+845,000
+9% +$12.5M 0.04% 438
2017
Q4
$136M Buy
9,507,928
+73,900
+0.8% +$961K 0.03% 524
2017
Q3
$107M Buy
9,434,028
+4,954,712
+111% +$87.6M 0.02% 599
2017
Q2
$81.9M Buy
4,479,316
+660,504
+17% +$12.2M 0.02% 701
2017
Q1
$80.9M Buy
3,818,812
+3,742,456
+4,901% +$73M 0.02% 706
2016
Q4
$1.14M Buy
76,356
+27,716
+57% +$491K ﹤0.01% 3373
2016
Q3
$1.07M Sell
48,640
-371,052
-88% -$8.26M ﹤0.01% 3100
2016
Q2
$8.32M Buy
419,692
+382,520
+1,029% +$6.51M ﹤0.01% 1956
2016
Q1
$631K Sell
37,172
-42,048
-53% -$702K ﹤0.01% 3264
2015
Q4
$1.62M Buy
79,220
+62,400
+371% +$1.3M ﹤0.01% 2864
2015
Q3
$362K Buy
+16,820
New +$375K ﹤0.01% 3536
2015
Q2
Sell
-265,676
Closed -$4.14M 4047
2015
Q1
$4.14M Buy
265,676
+243,704
+1,109% +$3.68M ﹤0.01% 2477
2014
Q4
$302K Buy
+21,972
New +$269K ﹤0.01% 3868
2014
Q3
Sell
-20,856
Closed -$207K 4198
2014
Q2
$207K Sell
20,856
-41,092
-66% -$364K ﹤0.01% 3363
2014
Q1
$641K Sell
61,948
-14,380
-19% -$149K ﹤0.01% 3043
2013
Q4
$676K Sell
76,328
-59,164
-44% -$468K ﹤0.01% 3332
2013
Q3
$956K Sell
135,492
-38,808
-22% -$246K ﹤0.01% 3296
2013
Q2
$978K Buy
+174,300
New +$835K ﹤0.01% 3273

Other funds holding DXCM

JP Morgan Chase's DXCM Position: Q2 2026 in Review

JP Morgan Chase reduced its DexCom (DXCM) stake by 45% in Q2 2026, selling an estimated $178M and leaving 3,325,095 shares worth $233M. The position accounts for 0.01% of the portfolio, ranked #696.

JP Morgan Chase first reported a position in DXCM in Q2 2013 and has held it in 51 quarters since. The position peaked at $1.64B in Q3 2021. 968 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • JP Morgan Chase held 3,325,095 shares of DexCom worth $233M as of Q2 2026.
  • JP Morgan Chase sold 2,674,375 DexCom shares in Q2 2026, an estimated $178M.
  • DexCom made up 0.01% of JP Morgan Chase's portfolio in Q2 2026, its #696 holding.
  • JP Morgan Chase first reported a position in DexCom in Q2 2013 and has held it in 51 quarters since.
  • JP Morgan Chase's DexCom position peaked at $1.64B in Q3 2021.
  • 968 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.